Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

John Christianson, Associate Professor at NDORMS, has been awarded a £2 million Cancer Research UK Senior Cancer Research Fellowship to explore new treatments for patients with multiple myeloma.

Cancer cells are often hallmarked by stress but take advantage of intrinsic protein homeostasis mechanisms to increase their resistance to stress-induced cell death. Multiple myeloma (MM) cancer cells rely heavily on endoplasmic reticulum-associated degradation (ERAD) to decrease the toxic levels of misfolded proteins that cause stress. Current therapeutic agents create more stress to induce MM cell death, but the robust and dynamically responsive ERAD mechanism elevates resistance to them which unwittingly supports cancer progression. The research will build on John’s previous work in proteostasis and ubiquitin biology to establish ERAD mediated by the Hrd1 ubiquitin ligase complex as a new therapeutic target in cancer. 

“This Fellowship is going to allow me to explore a new strategy for cancer intervention,” said John. “By understanding the fundamental nature of complexes responsible for protein degradation and the dynamic adaptability of quality control mechanisms, we can leverage that insight to develop compounds that impair or augment ERAD as a way to stop cancer cells from being able to grow.”

John has become a world-leader in his field researching the molecular mechanisms underpinning protein quality control in the ER, and in particular how specific substrates are identified and degraded by ER-associated ubiquitin ligases. 

Head of Department Professor Andrew Carr commented: “This exciting programme has the potential to lay the groundwork for the identification of new targets that may prove valuable for therapeutic intervention in cancer and other diseases associated with dysfunctional proteostasis, such as diabetes and neurodegeneration.”

Cancer Research UK Senior Fellowships support group leaders to further develop their own research programme and build their reputation as a world-leader in their cancer research field.

The research will start in January 2020 and run for six years.

Similar stories

Professor Sir Gordon Duff receives Honorary Senior Fellowship at NDORMS

Professor Sir Gordon Duff has been awarded an Honorary Senior Fellowship at NDORMS.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Afsie Sabokbar wins Lifetime Achievement at Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar wins Lifetime Achievement at 2021 Teaching Excellence Awards.

NDORMS staff recognised in the 2021 Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar, Associate Professor Stephanie Dakin and Graduate Studies Officer Samuel Burnell were all winners in the Teaching Excellence Awards.

Five ways to take action for your bone health

On World Osteoporosis Day, the International Osteoporosis Foundation (IOF), the world’s largest non-governmental organisation in the bone field, urges action for osteoporosis and fracture prevention.